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Abstract Autologous vaccines (short: autovaccines) have
been used since the beginning of the 20th century to treat
chronic staphylococcal infections, but their mechanisms of
action are still obscure. This prospective pilot study involved
four patients with furunculosis who were vaccinated with
autologous formalin-killed Staphylococcus aureus cells.
Vaccines were individually prepared from the infecting S.
aureus strain and repeatedly injected subcutaneously in
increasing doses over several months. We characterized the
virulence gene repertoire and spa genotype of the infecting
and colonising S. aureus strains. Serum antibody responses
to secreted and surface-bound bacterial antigens were
determined by two-dimensional immunoblotting and flow-
cytometry based assays (Luminex®). All patients reported
clinical improvement. Molecular characterization showed
that all strains isolated from one patient over time belonged
to the same S. aureus clone. Already before treatment, there
was robust antibody binding to a broad range of staph-
ylococcal antigens. Autovaccination moderately boosted the
IgG response to extracellular antigens in two patients, while
the antibody response of the other two patients was not
affected. Similarly, vaccination moderately enhanced the
antibody response against some staphylococcal surface pro-
teins, e.g. ClfA, ClfB, SdrD and SdrE. In summary, autovacci-
nation only slightly boosted the pre-existing serum antibody
response, predominantly to bacterial surface antigens.
Introduction
Besides being a common colonizer of human skin and
mucosa, Staphylococcus aureus also acts as a major human
pathogen. The species can cause a broad range of
infections, most frequently skin and soft tissue infections,
such as wound infections, furuncles, carbuncles and
abscesses, but also life-threatening systemic infections,
such as pneumonia and sepsis [1–3]. Furunculosis is a
common staphylococcal skin disease characterised by
painful, deep infections of the hair follicle. Even mild
lesions are painful and unsightly and often leave a scar after
they heal [4]. Antibiotic treatment is frequently not
effective, and many furunculosis patients suffer from
recurrent episodes or develop chronic symptoms [4].
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The alarming global spread of antibiotic resistant strains
has spurred efforts to develop active and passive anti-
staphylococcal vaccines [5, 6]. However, vaccine develop-
ment is a challenging task, because both the species S.
aureus and the host response that it induces are highly
variable. Two S. aureus strains can differ drastically in their
virulence gene content [7]. The variable genome consists of
mobile genetic elements such as pathogenicity islands and
phages that encode numerous virulence factors, including
toxins, exoenzymes and immune modulators [7–10]. In
concert with conserved virulence factors, these variable
bacterial compounds could determine differential patho-
genesis [11]. We observed a strong and strain-specific
antibody response against these variable antigens in S.
aureus carriers and during the natural course of S. aureus
bacteremia [12].
Active vaccination can be based on mono- or multivalent
subunit vaccines or on whole cell vaccines, which include
autologous vaccines (short: autovaccines) [6]. Autovaccines
are individually prepared from the autologous infecting
bacterial strain [13, 14]. Following subculture, the bacteria
and their secreted proteins are usually inactivated by
fixation, heat or cell lysis, and then repeatedly applied
orally or subcutaneously [13, 15]. In contrast to subunit
vaccines, autovaccines contain poorly characterized varie-
gated cocktails of surface proteins and secreted virulence
factors produced by the infecting strain.
Before the antibiotic era, chronic staphylococcal infec-
tions such as chronic furunculosis and osteomyelitis were
frequently treated by therapeutic vaccination with autolo-
gous formalin-killed S. aureus cells [14, 16–18]. Today,
autovaccination is still regularly performed in some Eastern
European countries, including Poland and the Czech
Republic [13, 19]. It is offered as a therapeutic alternative
to patients with chronic S. aureus infections that are
refractory to standard therapy. Moreover, bacterial whole
cell vaccines are commonly used in veterinary medicine to
treat chronic infectious diseases [20–22]. The major argu-
ment against the use of autovaccines in human medicine is
that safety and efficacy have not been determined in
controlled clinical trials. Moreover, the mode of action is
largely unknown.
In this prospective pilot study we analyzed if autovacci-
nation influences the serum antibody response to a broad
spectrum of secreted and surface-bound S. aureus antigens.
Materials and methods
Autovaccination patients
The Department of Medical Microbiology and Immunology
at the Pomeranian Medical University, Szczecin, Poland has
long-standing experience with autovaccination for therapy
of chronic S. aureus furunculosis and osteomyelitis [13].
This prospective pilot study included four patients (3
female and 1 male) from the Szczecin area. They suffered
from chronic or recurrent furunculosis and asked for
autovaccination, one of the treatment options in Poland.
In all four patients previous antibiotic treatment and
surgical intervention had been unsuccessful. Patient data
and anatomic location of the furuncles are shown in Table 1.
The patients showed no signs of immune suppression. All
four patients provided their written informed consent and
the study was approved by the Ethics Board of the
University of Szczecin.
S. aureus strains and sera
The S. aureus vaccine strains were isolated from infected
lesions (pus) during episodes of furunculosis. Moreover,
nasal swabs were taken repeatedly to determine the nasal
colonization status. S. aureus was identified on the basis of
generally accepted criteria: the presence of clumping factor
(slide test) and extracellular coagulase (tube test), and
biochemical identification (ID 32 Staph, BioMerieux). The
infecting and colonizing S. aureus isolates were stored as
glycerol stocks.
Antimicrobial susceptibility of isolates was estimated by
the disc diffusion method according to current recommen-
dations by the NCCLS/CLSI. Resistance to oxacillin/
cephoxitin was confirmed by detection of PBP 2′ (Slidex
MRSA detection, BioMerieux) and mecA PCR (see below).
Sera were obtained directly before and during autovacci-
nation treatment and stored at −80°C. We obtained four
consecutive serum samples from patient 6466 (day 0, 86,
273 and 332), three samples from patients 7293 (day 0, 42,
and 187) and 9105 (day 0, 85, and 166), and two samples
from patient 7510 (day 0, and 63). Additionally, control
sera from 11 healthy lab workers from the Department of
Microbiology and Immunology, Pomeranian Medical Uni-
versity, Szczecin (age 37.6±10.7 years; 36% male) were
analyzed.
Preparation of autologous vaccines
Autovaccines were individually prepared from the causa-
tive S. aureus strain, which was isolated from furunculosis
lesions. Autologous strains were cultivated for a maximum
of 24 h on oblique test tubes containing PPLO agar (Becton
Dickinson) supplemented with 10% (w/v) glucose and
0.1% (v/v) Tween 80. Bacteria were resuspended in 0.9%
NaCl solution and fixed with 0.4% formalin solution for
48 h. The bacterial suspension was adjusted to 5×108
bacteria/ml (suspension I), 1×109 bacteria/ml (suspension
II), and 2.5×109 bacteria/ml (suspension III) based on
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McFarland quantification. Afterwards, 0.1 mg/ml thiomer-
sal was added to these suspensions as preservative. Finally,
sterility of autovaccine preparation was tested by cultiva-
tion in thioglycollate medium (Becton Dickinson) for
7 days.
Administration of autovaccines
Autovaccines were prepared by the Department of Micro-
biology and Immunology, Pomeranian Medical University
in Szczecin, and administered by the patients’ general
practitioners. Before the beginning of treatment, a skin test
was performed to exclude hypersensitivity of the patient to
any of the vaccine components. Intradermally, 0.5 ml of a
1:10 dilution of suspension I in Aqua ad injectionem was
injected. Skin reaction was checked after 15 min and 24
hours. Autovaccines were then applied subcutaneously in
3–5 day intervals over 3 months. With each injection the
dose was increased based on the following application
scheme. Suspension I (5×108 bacteria/ml) was applied in
volumes of 0.1, 0.2, 0.3, 0.4 and 0.5 ml, followed by
suspension II (1×109 bacteria/ml; 0.3, 0.4, 0.5, 0.6, 0.7,
0.8, 0.9, 1.0 ml) and suspension III (2.5×109 bacteria/ml;
0.5, 0.6, 0.7, 0.8, 0.9, 1.0 ml). This immunization procedure
was followed by several recall injections (suspension III,
1 ml) every 1–3 weeks for up to 5–12 months. After each
injection the patients were closely monitored for 30 minutes
(swelling, pain or rash on injection side, blood pressure,
breathing). After every vaccination, presumptive systemic
symptoms (fever, headache, general malaise, sore throat,
etc.) were also analyzed by a physician to exclude any side
effects associated with autovaccination. Moreover, labora-
tory tests were performed before autovaccination and after
completion of the basic application scheme (blood count,
CRP; urine: proteinuria).
Clinical evaluation
The impact of autovaccination on the severity and
frequency of furunculosis was retrospectively analyzed
by reviewing the clinical records. Additionally, a tele-
phone interview using a questionnaire was performed by
Table 1 Clinical outcome of autovaccination
Patient data Patient 6466 Patient 7293 Patient 7510 Patient 9105
Age (y) 23 35 50 41
Gender Female Female Male Female
Risk factorsa Atopic dermatitis – – Atopic dermatitis
Onset of furuncles 02/06 07/06 2002 07/06
AV treatment 08/07–12/08 10/06–08/07 10/06–10/07 12/06–10/07
Location of furuncles Face, neck, axilla Axilla, abdomen, back Face, neck Axilla, buttocks
Mean number of episodes per month Before AV 2 4 2 3.5
During AV 0 1 2 0.2
After AV 1 0 0.6 0
Chronicity Before AV Intermittently Permanently Permanently Permanently
During AV Symptom free Intermittently Intermittently Intermittently
After AV Intermittently Symptom free Intermittently Symptom free
Single/multiple sites Before AV Multiple Multiple Multiple Multiple
During AV – Multiple(1 episode) Single Single
After AV Single – Single –
Severity scoreb Before AV 2 2 2 3
During AV 0 1 1 1
After AV 1 0 1 0
Clinical improvementc Strong Strong Moderate Strong
AV autovaccination
aRisk factors: atopic dermatitis, chronic wounds, gout, diabetes mellitus, COPD, cancer, chronic liver disease, cardiovascular disease, rheumatoid
diseases, HIV, chronic gut diseases (Morbus Crohn, Ulcerative Colitis), psoriasis, regular dialysis, immune suppressive drugs
bDisease severity was assessed based on a severity score. 0 – No furuncles/abscesses; 1 – Few small furuncles, self-healing in less than two weeks,
no medical intervention required; 2 – Furuncles of moderate severity, medical intervention required; 3 – Severe furuncles/carbuncles with strong
pain and large fluid collections, medical intervention required
cClinical improvement (classified as none, moderate or strong) based on the patients personal rating.
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a physician, which included questions about the chron-
icity, duration, location and severity of furuncles, as well
as a patient’s rating of the clinical improvement after
autovaccination.
Detection of S. aureus virulence factors by PCR
PCR was used to screen for a total of 26 virulence genes.
Single and multiplex-PCR were applied for the detection of
gyrase (gyr), methicillin resistance (mecA), Panton-
Valentine-leukocidin (pvl), staphylococcal enterotoxins
(sea-seu), toxic shock syndrome toxin 1 (tst), exfoliative
toxins (eta, etb, etd), and agr groups 1–4 as previously
reported [8].
spa genotyping
PCR for amplification of the S. aureus protein A (spa)
repeat region was performed according to the published
protocol [23, 24]. PCR products were sequenced by a
commercial supplier using both amplification primers
(Agowa, Berlin, Germany). The forward and reverse
sequence chromatograms were analyzed with the Ridom
StaphType software (Ridom GmbH, Würzburg, Germany).
Spa types were clustered into different clonal clusters using
the Based Upon Repeat Pattern (BURP) algorithm. Since
spa typing and multilocus-sequence typing (MLST) are
highly concordant, spa typing data could be mapped on
MLST types by using the SpaServer database (www.
spaserver.ridom.de).
2D-Immunoblots
Two-dimensional polyacrylamide gel electrophoresis (2-DE)
with mini 2D gels and 2D immunoblots (2D-IBs) were
performed as described [25]. Briefly, for antigen preparation,
bacteria were inoculated in tryptic soy broth (TSB) to an
optical density at 540 nm of 0.05 and cultivated in 100 ml
cultures at 37°C and 180 rpm. Cultures were harvested 3.5 h
after the bacterial culture entered the stationary phase,
extracellular proteins were collected, and protein concen-
tration was determined as previously described [11, 25].
Afterwards, isoelectric focusing was performed with
7 cm Immobiline Dry Strips of pI ranges 4–7 and 6–11
(GE Healthcare, Munich, Germany). Following separation
according to molecular mass in the second dimension, the
resolved staphylococcal proteins were blotted onto a PVDF
membrane (Immobilon-P, Millipore) and incubated with the
corresponding human sera at 1:10,000 dilution. IgG bind-
ing was detected by peroxidase-conjugated goat anti-human
IgG and visualized with an ECL substrate (SuperSignal
West Femto Maximum Sensitivity Substrate, Pierce).
Consecutive serum samples from one patient were always
analyzed simultaneously; at least three technical replicates
were performed for each patient.
Analysis of the 2D-IB images was performed with the
Delta-2D software package version 4.0 (Decodon GmbH,
Greifswald, Germany) as described [11, 25]. A fused image
of all IBs from one patient was obtained in a two-step
procedure. First, all IB images from one time course
experiment were matched with the most complex IB and a
fusion image was obtained using the union fuse option.
Second, the fusion images from the three technical replicates
were matched and fused. Spots on the fusion image were
automatically detected and manually validated by comparing
the original blot images with the fusion image. Subsequently,
the spot map and the corresponding labels from the fusion
image were transferred to all blot images from one patient.
For spot detection on IBs the signal intensity threshold was
set to 0.2 arbitrary units (AU).
Flamingo® protein staining
To correlate IB binding with protein abundance, represen-
tative IB images were matched with Flamingo®-stained 2D
gels. Gels were stained with the Flamingo® Fluorescent Gel
Stain (BioRad, Munich, Germany) according to the
manufacturer’s instructions.
Bead-based flow cytometry (Luminex®)
Serum IgG, IgA and IgM directed against a panel of 40
recombinant staphylococcal antigens was quantified using
the bead based flow cytometry technique (xMap®, Lumi-
nex Corporation, Austin, Texas, USA). Antigens comprised
surface proteins, such as clumping factor A and B (ClfA,
ClfB), and serine-aspartate dipeptide repeat proteins (SdrD
and SdrE), and secreted proteins, including toxins (super-
antigens, leukotoxins) and immune modulatory proteins
(CHIPS, SCIN, SSL proteins).
Methods were as described previously [26, 27]. Tests
were performed in independent duplicates and the median
fluorescence intensity (MFI) values, reflecting antibody
concentrations, were averaged. In each experiment, control
beads (no protein coupled) were included to determine non-
specific antibody binding. In case of non-specific binding,
this background was subtracted from the MFI values.
Human pooled serum was used as a standard.
Statistics
Differences in antibody binding (Luminex®) between
furunculosis patients and healthy controls were assessed
using the Mann-Whitney U test in conjunction with the
Benjamini-Hochberg false discovery rate (FDR) multiple
testing correction (FDR<0.05).
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Results
Clinical outcome of autovaccination
To assess the impact of autovaccination on the severity and
frequency of furunculosis, clinical records were screened and
telephone interviews using a questionnaire were performed by
a physician (Table 1). All four patients suffered from chronic
(7293, 7510, and 9105) or recurrent (6466) furunculosis,
which required repeated medical interventions.
Autovaccination reduced the frequency and severity of
furunculosis or resulted in complete remission (Table 1). Two
patients (7293 and 9105) were free of symptoms after
autovaccination treatment. The other two (6466, 7510)
still developed single, self-healing furuncles, which did
not require medical treatment. All patients reported
subjective improvement (Table 1). Side effects occasionally
observed by the patients were pain and inflammation at the
side of injection and elevated temperature (< 38°C) for two
days after injection.
Molecular characterization of the furunculosis strains
The infecting S. aureus strains were repeatedly isolated
from infected skin lesions. In parallel, nasal swabs were
taken to determine the nasal colonization status. The
infecting and colonizing S. aureus isolates were charac-
terized by spa genotyping. Additionally, a panel of
virulence genes, including pvl, mecA, exfoliative toxins
and superantigens was detected by multiplex PCR
(Table 2).
Three patients were nasal S. aureus carriers. Molecular
characterization showed that all S. aureus furunculosis and
nasal strains isolated from one patient over time belonged
to the same S. aureus clone. Notably, two patients (7293
and 9105) were infected with a community-acquired
methicillin-resistant S. aureus strain (CA-MRSA), which
belonged to the clonal cluster CC59. Both strains harbored
the characteristic mecA and pvl genes and displayed a
macrolide-lincosamide-streptogramin B resistance (MLSB)
phenotype. Nasal and infecting strains from patient 6466
were pvl-positive and belonged to CC121, a lineage
strongly associated with furunculosis [28]. Patient 7510
carried a pvl-negative CC8 isolate (Table 2).
Anti-staphylococcal serum antibodies
before autovaccination
Taking into account the pronounced variability of the
species S. aureus we used a personalized approach to study
the kinetics of the human antibody response in autovacci-
nation. Two-dimensional immunoblots (2D-IB) served to
analyze the binding of each patient’s serum antibodies to
the antigen spectra of the corresponding infecting S. aureus
strain. Our analyses were focused on the more informative
pH range of 6–11, where most extracellular proteins
resolve, while protein A is excluded, so that unspecific
IgG binding could be avoided [25].
The furunculosis patients showed a strong antibody
response against the extracellular proteins of their infecting
S. aureus strain already before autovaccination treatment
(Fig. 1a). All four patients showed a relatively complex
Table 2 Virulence genes and genotype of S. aureus strains
Clinical data Virulence genesa Genotype
Patient S. aureus isolate Date Source mecA pvl non-egc SAgs egc SAgs eta, etd agr spa type Deduced MLST CCb
6466 6466/1 22.06.07 Pusc − + − g i m n o u − 4 t645 CC121
6466 6466/2 20.08.07 Nose − + − g i m n o u − 4 t645 CC121
6466 6466/2a 14.11.07 Nose − + − g i m n o u − 4 t645 CC121
6466 6466/2b 17.07.08 Nose − + − g i m n o u − 4 t645 CC121
7293 7293/1 20.09.06 Pusc + + − − − 1 t437 CC59
7293 7293/2 20.09.06 Nose + + − − − 1 t437 CC59
7293 7293/2a 12.12.06 Nose + + − − − 1 t437 CC59
7510 7510/1 27.09.06 Pusc − − − g i m n o u − 4 t037 CC8
7510 7510/2 27.09.06 Nose − − − g i m n o u − 4 t037 CC8
7510 7510/1b 20.12.06 Pus − − − g i m n o u − 4 t037 CC8
9105 9105/1 20.11.06 Pusc + + b k q − − 1 t437 CC59
aStaphylococcal enterotoxins (SEs) are indicated by single letters (a = sea, etc.). tst = toxic shock syndrome toxin, egc = enterotoxin gene cluster,
eta, etd = exfoliative toxins a and d, agr = accessory gene regulator, pvl = Panton-Valentine leucocidine (lukPV).
bMLST CC nomenclature was deduced from spa types using the Ridom SpaServer database.
cThe strain isolated from purulent furuncles was used to prepare the autovaccine
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antibody binding pattern, especially in the basic pH range.
However, there were also numerous protein spots which
were not recognized by serum IgG. IB images from pH
4–7 were less complex and a number of spots were due
to IgG binding to protein A. Overall, they corroborate
the observations made in pH range 6–11 (data not
shown).
Next, Luminex® technology was used to compare the
antibody response in furunculosis patients (before autovac-
cination) and healthy controls. Anti-staphylococcal IgG,
IgA and IgM serum concentrations in the four investigated
patients were comparable to those in healthy individuals
(n=11) (Fig. 2). Serum IgG and IgA from furunculosis
patients reacted with a broad range of staphylococcal
Fig. 1 Serum IgG response to extracellular S. aureus proteins in
autovaccination. a Overlay images of Flamingo®-stained 2D gels and
corresponding 2D-immunoblots. The proteins released during post-
exponential growth by the four invasive S. aureus strains were
separated by 2D gel electrophoresis (pH 6–11) and stained with the
fluorescence protein dye Flamingo® (red). The four bacterial isolates
differed in their secretomes. In parallel, the extracellular bacterial
antigens were blotted onto PVDF membranes and incubated with the
corresponding patients’ sera obtained before autovaccination. The
overlay images (protein – red; IgG binding – blue) showed a strong
antibody response to the infecting strain already before autovaccina-
tion. b Kinetics of individual IgG responses to autovaccination.
Extracellular antigens from the infecting S. aureus strains were
separated by 2D gel electrophoresis and quantitative IBs were
performed with the corresponding patients’ sera obtained at different
time points. Overlays of 2D-IBs with sera obtained before (blue) and
during (orange) autovaccination. Autovaccination induced a moderate
boost in the IgG response. One out of the three technical replicates is
shown
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surface antigens, toxins (e.g. PVL, superantigens) and
immunomodulatory proteins. There was little IgM binding
to staphylococcal antigens in controls as well as two
patients, but strong binding to many S. aureus antigens in
the other two patients (Fig. 2). Superantigens encoded by
the enterotoxin gene cluster, egc, were on average bound
less strongly than others. To conclude, furunculosis patients
did not have a general lack of anti-staphylococcal antibodies.
Antibody response during autovaccination
To test whether autovaccination triggers an antibody response,
we studied the kinetics of antibody binding using 2D-IBs and
Luminex. First, we performed 2D-IBs with sera obtained over
the course of autovaccination (2–4 samples). Superimposition
of 2D-IB images from serum samples obtained before
autovaccination (blue) and later (orange) showed almost
identical antibody binding patterns as indicated by the
dominance of black spots on the superimposed images
(Fig. 1b). Only a few new IgG-binding specificities,
indicated by purely orange spots, were generated. Patient
7293 was exceptional, because we observed a boost in the
IgG-binding as well as numerous novel IB-spots.
Next, we quantified the individual IB-spot intensities
and determined the changes in antibody binding during
autovaccination (Fig. 3). The patients’ sera obtained before
autovaccination reacted with 55–82 protein spots. Patient
7293 showed the weakest antibody binding before vacci-
Fig. 2 Serum IgG, IgA and IgM response to S. aureus surface
proteins and toxins in furunculosis patients and healthy controls.
Serum IgG (a), IgA (b) and IgM (c) antibody binding to a panel of 40
S. aureus antigens was assessed with a Luminex assay and Ig binding
to individual antigens is depicted as median fluorescence intensity
(MFI). Each symbol represents a single individual. Median levels of
anti-staphylococcal antibodies for patients (n=4; before autovaccina-
tion) and healthy controls (n=11) are indicated. The antibody binding
patterns of furunculosis patients and healthy controls were not
significantly different (Mann-Whitney U test using the Benjamini-
Hochberg false discovery rate multiple testing correction). Abbrevia-
tions: ClfA Clumping factor A, Efb extracellular fibrinogen-binding
protein, FnbpA Fibronectin binding protein A, IsdA iron-responsive
surface determinant, Sas S. aureus surface protein, Sdr serine-aspartate
dipeptide repeat proteins, CHIPS chemotaxis inhibitory protein of S.
aureus, Luk leukocidin, SCIN staphylococcal complement inhibitor,
SSL staphylococcal superantigen-like protein, SE staphylococcal
enterotoxin
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nation (Fig. 3a). In this patient, vaccination induced a two- to
five-fold intensity increase in most spots (59/67) (Fig. 3b). A
moderate boost was observed in patient 7510 with 22/83
spots increasing more than two-fold. The antibody patterns
of the other two patients (6466 and 9105) remained almost
unchanged (Fig. 3b). Notably, autovaccination induced only
few novel antibody specificities. In conclusion, autovaccina-
tion boosted the IgG response to extracellular antigens in two
patients, while the antibody response of the other two
patients was not affected.
Finally, we applied the Luminex assay to test whether
autovaccines trigger an antibody response to surface-bound
staphylococcal antigens. Indeed, three out of four patients
showed a more than two-fold increase in IgG binding to
surface antigens, such as ClfA (7293, 7510, 9105), ClfB
(9105), SdrD (7510) and SdrE (7293) (Fig. 4). Similarly,
we observed a boost in the IgA response against surface
proteins (suppl. Fig. 1). Thus, vaccination induced a
moderate boost of the antibody response against staph-
ylococcal surface proteins. Novel antibody specificities
against surface proteins were not generated.
Discussion
Autovaccines have been applied in chronic staphylococcal
infections for decades, but their mechanism of action is still
unknown. In this pilot study, we demonstrate that autovac-
cination only slightly boosts the antibody response to
extracellular bacterial antigens and surface proteins.
This pilot study was not designed to test the efficacy
of autovaccination, but rather to characterize the kinetics
of the antibody responses. Therefore, we analyzed only a
small cohort and did not include placebo controls.
Moreover, some clinical outcome criteria (severity score,
rating of clinical improvement) are subjective, which
limits the evaluation of the clinical outcome. Never-
theless, it is interesting to note that based on the applied
criteria all four patients, two of whom were chronically
infected with CA-MRSA, clinically improved during
treatment. In the 1970s, Ring et al. reported that oral
autovaccination treatment improved the clinical state in
11/18 patients with chronic posttraumatic osteomyelitis
[15]. Similarly, a controlled study of 292 children with
paranasal sinusitis demonstrated that antibiotic therapy
plus autovaccine was superior to antibiotic therapy alone
[29]. Overall, little is published in English on the efficacy
and safety of autovaccination. In particular, prospective,
controlled, randomized, and, if possible, (double)-blind
clinical studies are lacking.
Already before autovaccination, the study patients had
serum antibodies that bound to a broad antigen spectrum
of their infecting S. aureus strain. There was no obvious
defect in their anti-staphylococcal antibody response.
Furunculosis patients suffer from chronic or recurrent
infection for many months or even years and, therefore,
the immune system is frequently and intensively exposed
to the invasive strain and establishes a memory response.
Moreover, most furunculosis patients are S. aureus carriers
and the nasal and infecting strains are usually identical
Fig. 3 Quantification of IgG binding to extracellular S. aureus
antigens. Spot intensities on 2D-IB were determined from three or
more replicate blots and median intensities in arbitrary units (AU) are
depicted. The threshold was set at a volume of 0.2 AU. a Spot
intensities before autovaccination. Before autovaccination, we
detected strong serum IgG binding to numerous antigens from the
infecting strain. The total number of immunoblot spots is displayed
above each data set. Median intensities from all spots are indicated. b
Changes of spot intensities during autovaccination. To monitor
changes in IgG binding, the ratios between the last and first serum
sample were calculated for each spot (ratios of median spot
intensities). In patient 7293 most spots showed a two- to five-fold
increase in IgG binding. Shaded area corresponds to a two-fold
change. The total number of immunoblot spots obtained with the last
serum is displayed above each data set. The overall medians are
depicted
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[28]. In this study, three out of four patients were
colonized with the infecting strain in the nose. Thus, the
nose appears to be a potential source for repeated
endogenous infections. In agreement with our findings of
a robust baseline anti-S. aureus antibody response in the
furunculosis patients, we previously reported that healthy
human carriers are pre-immunized with their colonizing
strain [12, 25].
By applying 2D-IB and Luminex assays we found that
autovaccination only slightly boosted the pre-existing anti-
body response to secreted bacterial antigens and surface
proteins. Notably, autovaccination did not induce a pro-
found de novo generation of antibody specificities. These
findings suggest that repeated subcutaneous immunization
does not strongly trigger the humoral immune response in
these well pre-immunized patients. In line with this,
Szkaradkiewicz et al. analyzed the IgG response in patients
treated with autovaccines using 1D-immunoblots and also
observed no changes in IgG binding patterns to S. aureus
polypeptides [30]. In contrast to autovaccination of furun-
culosis patients, systemic S. aureus infection strongly
enhances the anti-staphylococcal antibody response in
patients [10].
We previously reported a high degree of strain-
specificity in the anti-S. aureus antibody response [12].
However, it is also possible that some antibody specificities
are cross-reactive. For example, patient 6466 mounted an
antibody response against SEC, but the strain used for
Fig. 4 Kinetics of the serum IgG response to S. aureus surface
proteins and toxins over the course of autovaccination. IgG binding to
a panel of 40 S. aureus antigens was assessed with a Luminex assay.
Each graph represents a single patient. Per patient, the level of
antigen-specific antibodies in the time course of autovaccination is
shown. Arrows indicate a more than two-fold increase in antibody
binding. See legend to Fig. 2 for more detailed information on the
antigens
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autovaccination lacked the sec gene. SEC belongs to a
family of 21 staphylococcal superantigens with up to 90%
sequence homology, which could explain the observed
cross-reactivity [31, 32].
The pore-forming toxin PVL is epidemiologically
strongly linked to S. aureus furunculosis [3, 28]. In this
study, three out of four patients were infected with pvl-
positive strains. All patients had high levels of IgG
antibodies against both subunits of the toxin, LukF and
LukS, which did not increase during autovaccination.
Little is known about the mechanisms by which
autovaccines might influence the disease course or
impact on the immune response. Halasa et al. reported
that autovaccination increases the concentration of S.
aureus strain-specific agglutinating antibodies and enhan-
ces the phagocytosis of bacteria by peripheral blood
granulocytes [13]. Similarly, clinical improvement of acne
after autovaccination with killed Propionibacterium acnes
was accompanied by the generation of specific antibodies
against bacterial structures [33]. Still, it is difficult to
imagine that the observed moderate changes of antibody
titers should fully explain the clinical effects of the
treatment. Other groups have reported that autovaccination
down-regulates Th1 cell function and reduces delayed
type hypersensitivity reactions [15, 21, 34]. In conjunction
with the observation that T cells can influence the
recruitment and anti-bacterial action of granulocytes [35,
36], this opens an interesting perspective for research.
Moreover, the humoral immune response to non-protein
staphylococcal antigens, such as lipoteichoic acid, wall
teichoic acid and capsular polysaccharides, might be
clinically important and will be addressed in future
analyses [11, 37]. Finally, we cannot rule out that
formalin-fixation of the vaccine preparation influences
the three-dimensional antigen structure, which might
influence the antibody response, especially to surface
antigens.
The rapid spread of multiresistant S. aureus strains
enforces the development of new strategies to combat
staphylococcal infections. In view of the pronounced
variability of the bacterial species, personalized approaches
could hold promise for patients with recurrent or chronic S.
aureus infection. Autovaccination could serve as a model
that merits further investigation.
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